X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of “Hold” by Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given a consensus recommendation of “Hold” by the five research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $34.50.

XFOR has been the topic of several analyst reports. Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Wall Street Zen cut shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Finally, Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th.

X4 Pharmaceuticals Stock Up 0.3%

XFOR opened at $3.70 on Friday. The company has a market capitalization of $323.53 million, a PE ratio of -0.37 and a beta of 0.41. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $24.30. The business has a 50-day moving average of $3.82 and a 200-day moving average of $3.32.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10. The firm had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%. Equities research analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in XFOR. Nantahala Capital Management LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter valued at approximately $7,621,000. Rosalind Advisors Inc. bought a new stake in shares of X4 Pharmaceuticals during the 3rd quarter worth $5,283,000. Deep Track Capital LP acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at $3,839,000. Kingdon Capital Management L.L.C. grew its stake in X4 Pharmaceuticals by 300.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after buying an additional 700,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after acquiring an additional 178,593 shares during the period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.